IMMUNOME INC (IMNM)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for IMNM
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| IMNM | Director | 72 | ["M.B.A. from the Wharton School at the University of Pennsylvania","degree in economics from the Ecole Superieure de Commerce de Paris","extensive business and operating experience in the life sciences and biotechnology sectors","experience managing and serving on boards of public biotechnology companies"] | ["Audit","Compensation"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| INCY | Independent Director | 72 | ["Chief Executive Officer from May 2005 to November 2023 of BioMarin Pharmaceutical Inc.","Chair of the board of directors from June 2015 to November 2023 of BioMarin Pharmaceutical Inc.","Chair, Chief Executive Officer and President of Genencor","Chair, President and Chief Executive Officer of SangStat Medical Corporation","Various management positions at Rhône Poulenc Rorer Pharmaceuticals"] | ["Compensation (Chair)","Nominating and Corporate Governance","Nominating and Corporate Governance Committee"] | 2026 |
| BMRN | Chief Executive Officer; Former CEO | [] | [] | 2024 |
Biography sourced from the proxy statement filing.
Jean-Jacques Bienaim has served as a member of the Board since November 2023. Mr. Bienaim served as a member of the board of directors of BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a biotechnology company focused on genetic discovery, from May 2005 until May 2024, as its Chief Executive Officer from May 2005 until December 2023 and as its chairman of the board from June 2015 until December 2023. Mr. Bienaim served as Chairman, Chief Executive Officer and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics, from November 2002 to April 2005. Prior to Genencor, Mr. Bienaim served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation, an immunology-focused biotechnology company, from 1998 to late 2002, becoming President in 1998 and Chief Executive Officer in 1999. Mr. Bienaim also held several senior management positions at Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis) from 1992 to 1998, culminating in the position of Senior Vice President of Worldwide Marketing and Business Development. Earlier in his career, Mr. Bienaim worked at Genentech, Inc., where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. Mr. Bienaim also currently serves on the board of Incyte Corporation (NASDAQ: INCY), Keros Therapeutics, Inc. (NASDAQ: KROS) (and as Chairman since November 2025) and Ascendis Pharma A/S (NASDAQ: ASND), and he is a member of the board of Biotechnology Innovation Organization (BIO), an industry trade association. Mr. Bienaim received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the Ecole Superieure de Commerce de Paris. The Nominating Committee and the Board believe that Mr. Bienaim is qualified to serve on the Board due to his extensive business and operating experience in the life sciences and biotechnology sectors, including experience managing and serving on boards of public biotechnology companies.